Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.

Adv Ther · 2019 · PMC6860469 · PMID 31646466

Europe PMC DOI

hedged sentences

0.5630

closest p · 11.3× alpha

0.5630

boldest claim

The sentences

a numerical trendp = 0.563not close (p > 0.1)

− 4.4%; p = 0.042), although only a numerical trend for patients with microalbuminuria (≥ 30 to < 300 mg/g) in favor of lixisenatide was observed (− 16.2 vs. − 4.7; p = 0.563; data on file).

also in 1,012 other papers

did not reach statistical significanceno p-value reported

The 21.1% change in patients with microalbuminuria did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.